TY - JOUR
T1 - Long-term mortality of Dutch COVID-19 patients admitted to the intensive care medicine
T2 - a retrospective analysis from a national quality registry
AU - Wortel, Safira A
AU - Bakhshi-Raiez, Ferishta
AU - Abu-Hanna, Ameen
AU - Dongelmans, Dave A
AU - Keizer, Nicolette F de
AU - Houwink, Aletta
AU - Dijkhuizen, Allard
AU - Draisma, Annelies
AU - Rijkeboer, Annemiek
AU - Cloïn, Arjan
AU - Meijer, Arthur de
AU - Reidinga, Auke
AU - Festen-Spanjer, Barbara
AU - van Bussel, Bas
AU - Eikemans, Bob
AU - Jacobs, Cretièn
AU - Moolenaar, David
AU - Ramnarain, Dharmanand
AU - Koning, Dick
AU - Boer, Dirk
AU - Verbiest, Dirk
AU - van Slobbe-Bijlsma, Eline
AU - van Koppen, Ellen
AU - Rengers, Els
AU - van Driel, Erik
AU - Verweij, Eva
AU - van Iersel, Freya
AU - Brunnekreef, Gert
AU - Kieft, Hans
AU - Kreeftenberg, Herman
AU - Hené, Ilanit
AU - Janssen, Inge
AU - Drogt, Ionana
AU - van der Horst, Iwan
AU - Spijkstra, Jan Jaap
AU - Rozendaal, Jan
AU - Mehagnoul-Schipper, Jannet
AU - Erasmus, Jelle Epker
AU - Holtkamp, Jessica
AU - Lutisan, Johan
AU - van Oers, Jos
AU - Lens, Judith
AU - van Gulik, Laura
AU - van den Berg, Lettie
AU - Urlings-Strop, Louise
AU - Georgieva, Lyuba
AU - van Lieshout, Maarten
AU - Hoogendoorn, Marga
AU - Mos, Marissa Vrolijk-de
AU - Dutch COVID-19 Research Consortium
PY - 2024/12/20
Y1 - 2024/12/20
N2 - Objective: To describe the 12-month mortality of Dutch COVID-19 intensive care unit patients, the total COVID-19 population and various subgroups on the basis of the number of comorbidities, age, sex, mechanical ventilation, and vasoactive medication use. Methods: We included all patients admitted with COVID-19 between March 1, 2020, and March 29, 2022, from the Dutch National Intensive Care (NICE) database. The crude 12-month mortality rate is presented via Kaplan‒Meier survival curves for each patient subgroup. We used Cox regression models to analyze the effects of patient characteristics on 12-month mortality after hospital discharge. Results: We included 16,605 COVID-19 patients. The in-hospital mortality rate was 28.1%, and the 12-month mortality rate after intensive care unit admission was 29.8%. Among hospital survivors, 12-month mortality after hospital discharge was 2.5% (300/11,931). The hazard of death at 12 months after hospital discharge was greater in patients between 60 and 79 years (HR 4.74; 95%CI 2. 23-10. 06) and ≥ 80 years (HR 22. 77; 95%CI 9.91-52.28) than in patients < 40 years of age; in male patients than in female patients (HR 1.38; 95%CI 1.07-1.78); and in patients with one (adjusted HR 1.95; 95%CI 1.5-2.53), two (adjusted HR 4.49; 95%CI 3.27-6.16) or more than two comorbidities (adjusted HR 4.99; 95%CI 2.62-9.5) than in patients with no comorbidities. Neither vasoactive medication use nor mechanical ventilation resulted in statistically significant results. Conclusion: For Dutch COVID-19 intensive care unit patients, most deaths occurred during their hospital stay. For hospital survivors, the crude 12-month mortality rate was low. Patient age (older than 60), sex and the number of comorbidities were associated with a greater hazard of death at 12 months after hospital discharge, whereas mechanical ventilation and vasoactive medication were not.
AB - Objective: To describe the 12-month mortality of Dutch COVID-19 intensive care unit patients, the total COVID-19 population and various subgroups on the basis of the number of comorbidities, age, sex, mechanical ventilation, and vasoactive medication use. Methods: We included all patients admitted with COVID-19 between March 1, 2020, and March 29, 2022, from the Dutch National Intensive Care (NICE) database. The crude 12-month mortality rate is presented via Kaplan‒Meier survival curves for each patient subgroup. We used Cox regression models to analyze the effects of patient characteristics on 12-month mortality after hospital discharge. Results: We included 16,605 COVID-19 patients. The in-hospital mortality rate was 28.1%, and the 12-month mortality rate after intensive care unit admission was 29.8%. Among hospital survivors, 12-month mortality after hospital discharge was 2.5% (300/11,931). The hazard of death at 12 months after hospital discharge was greater in patients between 60 and 79 years (HR 4.74; 95%CI 2. 23-10. 06) and ≥ 80 years (HR 22. 77; 95%CI 9.91-52.28) than in patients < 40 years of age; in male patients than in female patients (HR 1.38; 95%CI 1.07-1.78); and in patients with one (adjusted HR 1.95; 95%CI 1.5-2.53), two (adjusted HR 4.49; 95%CI 3.27-6.16) or more than two comorbidities (adjusted HR 4.99; 95%CI 2.62-9.5) than in patients with no comorbidities. Neither vasoactive medication use nor mechanical ventilation resulted in statistically significant results. Conclusion: For Dutch COVID-19 intensive care unit patients, most deaths occurred during their hospital stay. For hospital survivors, the crude 12-month mortality rate was low. Patient age (older than 60), sex and the number of comorbidities were associated with a greater hazard of death at 12 months after hospital discharge, whereas mechanical ventilation and vasoactive medication were not.
KW - Humans
KW - COVID-19/mortality therapy epidemiology
KW - Male
KW - Female
KW - Netherlands/epidemiology
KW - Middle Aged
KW - Aged
KW - Retrospective Studies
KW - Hospital Mortality
KW - Aged, 80 and over
KW - Intensive Care Units/statistics & numerical data
KW - Registries
KW - Respiration, Artificial/statistics & numerical data
KW - Comorbidity
KW - Adult
KW - SARS-CoV-2
KW - Age Factors
U2 - 10.62675/2965-2774.20240251-en
DO - 10.62675/2965-2774.20240251-en
M3 - Article
SN - 2965-2774
VL - 36
JO - Critical Care Science
JF - Critical Care Science
M1 - e202400251en
ER -